Board of Directors

Jean-Marc Huët

Chair of the Board of Directors of Lonza Group Ltd (since May 2024), Independent member of the Board of Directors of Lonza Group Ltd (since May 2024).
Jean-Marc Huët was elected as Chair of the Board of Directors at the 2024 Annual General Meeting. Jean-Marc brings a strong international leadership track record, with current Chair roles at Heineken and Vermaat, among other senior responsibilities.

He has extensive international strategic leadership experience in the consumer, pharma and nutrition industries, having previously served as Chief Financial Officer of Unilever, Bristol-Myers Squibb and Royal Numico.

He holds an MBA from INSEAD, Fontainbleau (FR).

Current Activities and Functions

Jean-Marc Huët is the Chair of the Nomination and Governance Committee, which is responsible for overseeing governance, talent development, and succession planning for the Board and Executive Committee.

He is also a member of the Strategy Innovation Committee, which is responsible for reviewing innovation and technology initiatives at Lonza, including ESG developments.

Public Company Boards:

• Chair, Heineken Holding NV (since 2025)

Further Appointments:

• Chair, Vermaat (since 2019)

Former Activities and Functions

• Chair, Heineken NV (2014 - 2025)
• Member of the Board of Picnic (2020 – 2024)
• Member of the Board of Canada Goose (2017 – 2023)
• Member of the Board of SHV (2015 – 2019)
• Member of the Board of Formula One (2012 – 2017)
• Member of the Board of Mead Johnson Nutrition (2009)
• Executive Director and Chief Financial Officer, Unilever (2010 – 2015)
• Executive Vice President and Chief Financial Officer, Bristol-Myers Squibb (2008 – 2009)
• Member of Executive Board and Chief Financial Officer, Royal Numico (2003 – 2007)
• Executive Director, Investment Banking, Goldman Sachs International (1993 – 2003)
• Commercial Manager, Clement Trading (1991 – 1993)

---

Jürgen Steinemann

Vice-Chair of the Board of Directors of Lonza Group Ltd (since August 2024); Independent member of the Board of Directors of Lonza Group Ltd (since April 2014)

Jürgen Steinemann holds a degree in Economics and Business Management from the European Business School in Wiesbaden (DE), London (UK) and Paris (FR).

Current Activities and Functions

Jürgen Steinemann is a member of the Remuneration Committee, which is responsible for reviewing and recommending compensation policies and plans, agreeing employment terms and evaluating the performance of the Executive Committee and the Chief Executive Officer.

He is also a member of the Nomination and Governance Committee, which is responsible for overseeing governance, talent development, and succession planning for the Board and Executive Committee.

• Managing Director of JBS Holding GmbH (since 2017)
• Chair of the Supervisory Board of Barentz International B.V. (since 2020)
• Member of the Supervisory Board of Bankiva B.V. (since 2017)
• Deputy Chair of the Supervisory Board of Big Dutchman AG (since 2023)

Former Activities and Functions

• Chair of the Supervisory Board of Metro AG (2015-2025)
• Chair ad interim of the Supervisory Board of Big Dutchman AG (2024 – 2025)
• Member of the Supervisory Board of Big Dutchman AG (2015 - 2023)
• Member of the Advisory Board of Tower Brook Capital Partners LP (2017-2022)
• Member of the Advisory Board of EQT (2019 – 2023)
• Member of the Board of Directors of Barry Callebaut AG (2015–2020)
• Chief Executive Officer of Barry Callebaut (2009–2015)
• Member of the Executive Board and Chief Operating Officer of Nutreco (2001–2009)
• Chief Executive Officer of Loders Croklaan (1999–2001)
• Various senior positions in business-to-business marketing and sales with the former Eridania Béghin-Say Group, ultimately in the «Corporate Plan et Stratégie» unit at the head office in Paris (1990–1998)
• Member of the Board of NGO African Parks Germany (2019 – 2023)

---

Christoph Mäder

Lead Independent Director of the Board of Directors of Lonza Group Ltd (since November 2019); Independent member of the Board of Directors of Lonza Group Ltd (since April 2016)

Christoph Mäder holds a Master’s degree in law from the University of Basel (CH) and is admitted to the Swiss Bar.

Current Activities and Functions

Christoph Mäder is the Chair of the Remuneration Committee, which is responsible for reviewing and recommending compensation policies and plans, agreeing employment terms and evaluating the performance of the Executive Committee and the Chief Executive Officer.

He is also a member of the Audit and Compliance Committee, which is in charge of overseeing the systems of internal control and financial reporting, and compliance with laws and regulations, including the reporting and assurance process for ESG.

Public Company Boards:

• Member of the Board of Directors Schindler Holding Ltd (since 2024)
• Member of the Board of Directors Baloise Holding Ltd (since 2019)

Further Appointments:

• Member of the Bank Council, Swiss National Bank (since 2021)
• President of Economiesuisse (since 2020) 
• Member of the Board of Directors Assivalor AG (since 2019)
• Member of the Advisory Board of Accenture Switzerland (since 2019)
• Partner at the law firm Becker | Gurini | Partner (since 2019)
• Member of the Council of Schweizer Jugend forscht (since 2018)
• Member of the Advisory Board of Vereinigung Schweizerischer Unternehmen in Deutschland (since 2016)
• Member of the Advisory Board of Loeba GmbH (since 2014)

Former Activities and Functions

• Vice-Chair of the Board of Directors of Lonza Group Ltd (2020–2024)
• Member of the Board of EMS Chemie Holding AG (2018–2023)
• Member of the Group Executive Committee of Syngenta (2000–2018)
• Member of the Board Committee of economiesuisse (2008–2019)
  
• Member of the Executive Board of the Business and Industry Advisory Committee (BIAC) for the Organization for Economic Co-operation and Development (OECD) (2012–2016)
• Member of the Board of scienceindustries (2006–2018)
• Member of the Board of the Basel Chamber of Commerce (2002–2018)
• Head of Legal & Public Affairs for Novartis Crop Protection AG (1999–2000)
• Senior Corporate Counsel for Novartis International AG (1992–1998)

---

Juan Andres

Independent member of the Board of Directors of Lonza Group Ltd (since May 2025).

Juan Andres has a career spanning more than 35 years during which he has held a variety of executive leadership positions. He was President, Strategic Partnerships and Enterprise Expansion at Moderna and led all manufacturing and technical development there during the COVID-19 pandemic. Prior to that, he led manufacturing worldwide and held other strategic roles at Novartis for 12 years, after spending more than 15 years at Eli Lilly. He has a deep strategic understanding of technical operations and quality that is complemented by international business expertise.

Juan holds a Master of Pharmacy from Alcala de Henares University (ES) and has completed the Accelerated Development Program at London Business School (UK).

Current Activities and Functions

Juan Andres is a member of the Nomination and Governance Committee, which is responsible for overseeing governance, talent development, and succession planning for the Board and Executive Committee.

He is also a member of the Strategy Innovation Committee, which is responsible for reviewing innovation and technology initiatives at Lonza, including ESG developments.

Public Company Boards:

• Independent Member of the Board of Directors, Avantor (since 2019)

Former Activities and Functions

• Independent Member of the Board of Directors, Evelo Biosciences (2019 – 2023)
• President, Strategic Partnerships and Enterprise Expansion, Moderna (2017 – 2023)
• Chief Technical Operations and Quality Officer, Moderna (2018 – 2022)
• SVP Technical Development, Manufacturing and Quality, Moderna (2017 – 2018)
• Head of Technical Operations, Novartis (2015 – 2017)
• Head of Global Technical Operations, Novartis (2013 – 2015)
• Group Head of Quality, Novartis (2009 – 2012)
• Global Head of Technical Research and Development, Novartis (2007 – 2009)
• Global Head of Pharmaceutical Operations, Novartis (2005 – 2007)
• Global Vice President, Pharmaceutical Manufacturing, Eli Lilly & Company (2002 – 2005)
• Various quality, production and site head roles for Eli Lilly & Company (1988 – 2004)

---

Eric Drapé

Independent member of the Board of Directors of Lonza Group Ltd (since May 2025).

For more than 35 years, Eric Drapé has served in multiple leadership roles in the pharmaceutical industry at Teva Pharmaceuticals, Ipsen Pharma and Novo Nordisk. He has a wealth of international experience, having held positions in Denmark, France, Israel and the US.

Eric holds a Doctorate in Pharmacy and a DESS in Analytical Chemistry from Paris XI (FR). He also holds an Executive MBA from SIMI (now Copenhagen Business School) (DK).

Current Activities and Functions

Eric Drapé is a member of the Remuneration Committee, which is responsible for reviewing and recommending compensation policies and plans, agreeing employment terms and evaluating the performance of the Executive Committee and the Chief Executive Officer.

He is also a member of the Audit and Compliance Committee, which is in charge of overseeing the systems of internal control and financial reporting, and compliance with laws and regulations, including the reporting and assurance process for ESG.

Public Company Boards:

• Independent Member of the Board of Directors, Laboratoires Guerbet (since 2025)

Further Appointments:

• Independent Member of the Board of Directors, LFB (since 2018)

Former Activities and Functions

• EVP, Head of Global Operations, Company Officer and Member of the Executive Committee, Teva (2019 – 2024)
• Member of the Board, Teva-Takeda Business Venture, Japan (2017 – 2022)
• EVP and Chief Quality Officer, Teva (2015 – 2019)
• Head of Biologics Operations, Teva (2014 – 2017)
• Senior VP, Technical Operations Steriles, Respiratory and Biologics, Teva (2014 – 2015)
• Executive VP, Technical Operations, Ipsen Pharma (2007 – 2014)
• Independent Member of the Board of Directors, NNE Pharmaplan France (2004 – 2007)
• Senior VP, Diabetes Finished Products, Novo Nordisk (2004 – 2007)
• Independent Member of the Board of Directors, A3P (1994 – 2001)
• Increasingly senior roles in Quality and as a Site Head in Novo Nordisk (1990 – 2004)
• Analytical Development roles in Air Force R&D and Servier (1987 – 1990)

---

Marion Helmes

Independent member of the Board of Directors of Lonza Group Ltd (since May 2022).

Marion Helmes has extensive financial expertise as well as global operational experience from a career that includes Chief Financial Officer positions at Celesio, Q-Cells and with ThyssenKrupp’s Elevator and Stainless divisions. She currently holds Board Memberships with Siemens Healthineers AG and Heineken N.V.

Marion has a degree in Business Administration from Freie Universität Berlin and a PhD from the University of St. Gallen.

Current Activities and Functions

Marion Helmes is a member of the Audit and Compliance Committee, which is responsible for overseeing the systems of internal control and financial reporting, and compliance with laws and regulations, including the reporting and assurance process for ESG.

She is also a member of the Nomination and Governance Committee, which is responsible for overseeing governance, talent development, and succession planning for the Board and Executive Committee.

Public Company Boards:

• Member of the Board of Directors, Chair of the Audit Committee of Heineken N.V. (since 2018)
• Member of the Board of Directors, Chair of the Audit Committee of Siemens Healthineers AG (since 2018)

Former Activities and Functions

• Vice Chair of the Board of Directors of ProSiebenSat.1 Media SE (2014–2023)
• Member of the Board of Directors of British American Tobacco plc (2016–2022)
• Member of the Board of Directors of Uniper SE (2017–2020)
• Member of the Board of Directors of Bilfinger SE (2016–2018)
• Member of the Board of Directors of NXP Semiconductors N.V. (2013–2018)
• Chief Financial Officer, Celesio AG. From 2013, Speaker of the Management Board (2012–2014)
  
• Member of the Board of Directors of Fugro N.V. (2009–2014)
• Chief Financial Officer, Q-Cells SE (2010–2011)
  
• Chief Financial Officer, ThyssenKrupp Elevator AG (2006–2010)
• Chief Financial Officer, ThyssenKrupp Stainless AG (2005–2006)
• Various positions in Mergers & Acquisitions, Corporate Development and Controlling, ThyssenKrupp AG (1997–2005)
• Project Manager, St. Gallen Consulting Group (1996–1997)
• Manager Restructuring, Privatisation, Treuhandanstalt (1991–1994)

---

Angelica Kohlmann

Independent member of the Board of Directors of Lonza Group Ltd (since May 2018).

Angelica Kohlmann holds a MD and doctorate in medicine from Hamburg University (DE).

Current Activities and Functions

Angelica Kohlmann is the Chair of the Innovation and Technology Committee, which is responsible for reviewing innovation and technology initiatives at Lonza, including ESG developments.

She is also a member of the Remuneration Committee, which is responsible for reviewing and recommending compensation policies and plans, agreeing employment terms and evaluating the performance of the Executive Committee and the Chief Executive Officer.

• Chair Board of Directors, Bloom Diagnostics AG (since 2018)
• Member International Advisory Board IE University and Business School, Madrid (since 2017)
• Chair Board of Directors, Kohlmann & Co AG (since 2013)
• International investor in biotech and tech, based in Switzerland (since 2014)
• Chair of the Advisory Board Peter Drucker Society Europe / Global Peter Drucker Forum, Vienna (since 2009)

Former Activities and Functions

• Board Observer Teralytics AG (2017-2023)
• Member Advisory Board UBS Unique (2017–2018)
• Director Trinnacle Fund Ltd (2016–2017)
• Member Board of Directors Teralytics AG (2013–2016)
• Founder & CEO Ifitech GmbH, Germany (2010–2017)
• International investor in biotech and tech, based in Germany (2000–2013)
• International consultant for strategy, management, investments and restructuring (1992–1999)
• Head global restructuring Behringwerke AG, Germany (1990–1992)
• Member Board Staff Hoechst AG, Germany (1988–1990)
• International Marketing Group Leader at Behringwerke AG (1986–1988)
• MD Anderson Cancer Center, Houston and Memorial Sloan Kettering Cancer Center, New York, USA – various cancer research functions

---

David Meline

Independent member of the Board of Directors of Lonza Group Ltd (since May 2025).

David has served as CFO of three publicly listed industrial and biotech companies and worked in various capital-intensive industries throughout his career. After serving as CFO and CAO of 3M Company as well as CFO of Amgen, one of the world’s largest independent biotech companies, David was CFO of Moderna during the COVID-19 pandemic. He has extensive governance, financial and industry experience, including business and IT services.

David holds a bachelor’s degree in Mechanical Engineering from Iowa State University (US), a master’s degree in Economics from London School of Economics (UK), and an MBA in Finance from the University of Chicago (US).

Current Activities and Functions

David Meline is a member of the Remuneration Committee, which is responsible for reviewing and recommending compensation policies and plans, agreeing employment terms and evaluating the performance of the Executive Committee and the Chief Executive Officer.

He is also a member of the Audit and Compliance Committee, which is in charge of overseeing the systems of internal control and financial reporting, and compliance with laws and regulations, including the reporting and assurance process for ESG.

Public Company Boards:

• Member of the Board, Member of the Finance, Investment and Technology Committee (since 2023), Chair of the Audit Committee (since 2024), HP Inc.
• Non-Executive Member of the Board, and Chair of the Finance, Audit and Compliance Committee, ABB Ltd (since 2016)

Further Appointments:

• Vice-Chair of the Board of Directors, Los Angeles Philharmonic, a non-profit organization (since 2016)

Former Activities and Functions

• Member of the Board and Member of the Audit Committee, Pacific Biosciences of California, Inc. (2023 - 2025)
• Chief Financial Officer, Moderna (2020 – 2022)
• Chief Financial Officer, Amgen (2014 – 2019)
• Chief Financial Officer, 3M Company (2011 – 2014)
• Corporate Controller and Chief Accounting Officer, 3M Company (2008 – 2011)
• Chief Financial Officer North America, General Motors (2007 – 2008)
• Chief Financial Officer Europe, General Motors (2004 – 2007)
• Chief Financial Officer Daewoo, General Motors (2002 – 2004)
• Chief Financial Officer Brazil, General Motors (2000 – 2001)
• Finance and management roles in Brazil, Kenya and the US (1986 – 1999)
• Product Design Engineer, AT&T (1980 – 1983)

---

Roger Nitsch

Independent member of the Board of Directors of Lonza Group Ltd (since May 2022).

Roger Nitsch serves as CEO and President of Neurimmune, which he founded in 2006 with two business partners. A neuroscientist with a background in medicine, Roger is recognized as an opinion leader in neurodegenerative diseases with over 30 years of experience in Alzheimer’s disease research and drug development. A Potamkin Prize winner and Member of the German Academy of Sciences, Roger served as a founding director of the Institute for Regenerative Medicine (IREM), University of Zurich.

Roger Nitsch holds an MD degree from the University of Heidelberg and earned his post-doctoral qualification at the Massachusetts Institute of Technology and Harvard Medical School.

Current Activities and Functions 

Roger Nitsch is a member of the Strategy Innovation Committee, which is responsible for reviewing innovation and technology initiatives at Lonza, including ESG developments.

He is also a member of the Nomination and Governance Committee, which is responsible for overseeing governance, talent development, and succession planning for the Board and Executive Committee.

• CEO and President of the Board of Directors of Neurimmune Group (since 2006)
• Member of the Advisory Board of PUREOS Bioventures (since 2017)
• Member of the Board of Directors of NOVAGO Therapeutics AG (since 2015)
  
• Member of the Board of Directors of INTEGRA Biosciences Holding AG (since 2002)
  

Former Activities and Functions

• Professor at the University of Zurich (1998-2024)
• Director and co-founder of the Institute for Regenerative Medicine University of Zurich (2016–2020)
• Overseas Visiting Professor of Health Science Aino University, Osaka, Japan (2016–2018)
• Member of the Advisory Board Max-Planck-Institute for Psychiatry, Munich (2009–2012)
• Member and Chair of the Scientific Advisory Board Institute for Advanced Studies (2006–2012)
• Chair, Board of Trustees, Center for Clinical Research University Hospital Zurich (2002–2014)
• Vice Dean Research, Medical Faculty at the University of Zurich (2002–2008)
• Coordinator of the European Union DIADEM and APOPIS Research Consortia (1999–2006)
• Director at the Psychiatric University Hospital Zurich (1998–2005)
• Member of the Board of Directors and co-founder EVOTEC Neurosciences (1995–1998)
• Post-Doc, M.I.T. and Harvard Medical School (1990–1995)
• Post-Doc, University of Heidelberg (1987–1990)
• Research Fellow, Max-Planck Institute for Medical Research, Heidelberg (1983–1987)

---

Barbara Richmond

Independent member of the Board of Directors of Lonza Group Ltd (since April 2014).

Barbara Richmond holds a first-class degree in management science from the University of Manchester Institute of Science and Technology in England. Barbara Richmond has substantial knowledge as a financial expert, demonstrated by her roles as CFO for various companies. She is a Fellow of the Institute of Chartered Accountants in England and Wales.

Current Activities and Functions

Barbara Richmond is the Chair of the Audit and Compliance Committee, which is responsible for overseeing the systems of internal control and financial reporting, and compliance with laws and regulations, including the reporting and assurance process for ESG. From August 2024 until retirement in August 2025, Barbara acts as Integration and Synergies Director Redrow.

Public Company Boards:

• Member of the Board of Directors of Barry Callebaut AG (since 2024)

Former Activities and Functions

• Group Finance Director of Redrow plc (2010 – 2024)
• Group CFO of Inchcape plc (2006–2009)
• Non-Executive Director and Audit Committee Chair of Scarborough Building Society until its merger with The Skipton Building Society (2005–2009)
• Non-Executive Director, Senior Independent Director and Audit Committee Chair of Carclo Group plc (2000–2006)
• Group CFO of Croda International plc (1997–2006) with dual role as Group CFO and President of Active Ingredients and Industrial Chemicals from 2002 to 2006
• Group CFO of Whessoe plc in 1993 (1993–1997)
• Various financial roles in Alstom Group SA (1987–1992)
• Auditor and management consultant for Arthur Andersen (1981–1984)

---